Science News for ACC.21

The American Heart Association's Science News from ACC.21 coverage brings you results and insights into selected important scientific trials presented at ACC.21, a virtual conference held May 15-17, 2021. Find at-a-glance data summaries, exclusive interviews, simultaneous publications, and more – all in one place.

Jump to one day's coverage: Saturday  |  Sunday  |  Monday

Quick Reference:
AHA Journals Simultaneous Publications

Prospective Arni Versus Ace Inhibitor Trial To Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction
Marc A. Pfeffer, MD, PhD | Distinguished Dzau Professor of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA

• RESULTS: PARADISE-MI: Heart Failure drug sacubitril/valsartan does not outperform ACE inhibitor after heart attack 
• ClinicalTrials: NCT02924727
• PARADISE-MI Presentation Slides (PDF)
• PARADISE-MI Data Summary Slide (PDF)

Aspirin Dosing: A Patient-centric Trial Assessing Benefits And Long-term Effectiveness Trial
Schuyler Jones, MD | Duke University Medical Center, Durham, NC

• RESULTS: ADAPTABLE: Low-dose aspirin is as effective and safe as a higher dose in secondary prevention of cardiovascular events
• ClinicalTrials: NCT02697916
• ADAPTABLE Trial Home
• ADAPTABLE Presentation Slides (PDF)
• ADAPTABLE Data Summary Slide (PDF)

Effects Of Dapagliflozin On Prevention Of Major Clinical Events And Recovery In Patients With Respiratory Failure Due To COVID-19 - Main Results From The DARE-19 Randomized Trial
Mikhail Kosiborod, MD | Saint Luke's Mid America Heart Institute, Kansas City, MO

• RESULTS: DARE-19 failed to capture enough events to achieve statistical significance on its primary endpoints, but suggests dapagliflozin is safe for COVID-19 patients
• Clinical Trials: NCT04350593
• DARE-19 Presentation Slides (PDF)
• DARE-19 Data Summary Slide (PDF)

Care Optimization Through Patient And Hospital Engagement Clinical Trial For Heart Failure: Primary Results Of The Connect-hf Randomized Clinical Trial
Adam D. DeVore, MD, MHS | Duke Clinical Research Institute, Durham, NC

• RESULTS: Extending existing hospital-based quality improvement efforts through audit, feedback, and education did not improve clinical outcomes or quality of care for patients with heart failure with reduced left ventricular ejection fraction.
• Clinical Trials: NCT03035474
• CONNECT-HF Presentation Slides (PDF)
• CONNECT-HF Data Summary Slide (PDF)

Acute Alcohol Consumption And Discrete Atrial Fibrillation Events
Gregory M Marcus, MD, MAS | University of California, San Francisco, San Francisco, CA

• RESULTS: HOLIDAY Monitors Study: Acute alcohol consumption found to be associated with discrete atrial fibrillation events.
• Clinical Trials: NCT01996943
• HOLIDAY Monitors Study Presentation Slide (PDF)
• HOLIDAY Monitors Study Data Summary Slide (PDF)

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol
Siri Lagethon Heck, et al. | Circulation | May 16, 2021

Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS
Kristina Lambrakis, et al. | Circulation | May 16, 2021

Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure with Preserved Ejection Fraction
Senthil Selvaraj, et al. | JAHA | May 16, 2021

Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Arash A Nargesi, et al. | JAHA | May 15, 2021

Temporal Trends, Clinical Characteristics and Outcomes of Emergent Coronary Artery Bypass Grafting for Acute Myocardial Infarction in the United States
Sri Harsha Patlolla, et al. | JAHA | May 15, 2021

Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry
Sameed Ahmed M, et al. | Circulation: Heart Failure | May 15, 2021

Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction
Sean P. Murphy, et al. | Circulation: Heart Failure | May 15, 2021

Social Determinants of Adherence to COVID-19 Risk Mitigation Measures Among Adults with Cardiovascular Disease
Kobina K., et al. | Circulation: Cardiovascular Quality and Outcomes | May 6, 2021

Hospital Variation in 30‐Day Readmissions Following Transcatheter Aortic Valve Replacement
Dhaval Kolte., et al. | JAHA | May 3, 2021